← Back to Clinical Trials
Recruiting NCT06172907

NCT06172907 A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06172907
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-04-19
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
Young Adults Coping with Cancer Together Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-04-19 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this pilot study is to examine the feasibility and acceptability of a brief psychotherapy intervention to improve psychosocial coping and maintain couple relationships among young adults (aged 25-39) with cancer and their caregiving partners.

Eligibility Criteria

Inclusion Criteria: * Either: (1) Currently receiving active cancer treatment (n=5) or are within two years of completing active treatment (n=5) at Massachusetts General Cancer Center (MGHCC), located in Boston, Massachusetts, United States, OR (2) are the partner of an individual between the ages of 25-39 who is currently receiving treatment at MGHCC (n=5) or who has completed cancer treatment at MGHCC within the past two years (n=5) * Either: (1) Indicates a score ≥4 on the National Comprehensive Cancer Network (NCCN) adapted distress thermometer study screening questions, OR (2) are the partner of a participant indicating a score ≥4 on the NCCN adapted distress thermometer study screening questions * English-speaking Exclusion Criteria: • Uncontrolled psychosis, active suicidal ideation, or cognitive impairment

Contact & Investigator

Central Contact

Jamie M Jacobs, Ph.D.

✉ jjacobs@mgh.harvard.edu

📞 617-643-1777

Principal Investigator

Jamie M Jacobs, Ph.D.

PRINCIPAL INVESTIGATOR

Massachusetts General Hospital

Frequently Asked Questions

Who can join the NCT06172907 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 39 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06172907 currently recruiting?

Yes, NCT06172907 is actively recruiting participants. Contact the research team at jjacobs@mgh.harvard.edu for enrollment information.

Where is the NCT06172907 trial being conducted?

This trial is being conducted at Boston, United States, Concord, United States, Danvers, United States, Newton, United States.

Who is sponsoring the NCT06172907 clinical trial?

NCT06172907 is sponsored by Massachusetts General Hospital. The principal investigator is Jamie M Jacobs, Ph.D. at Massachusetts General Hospital. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology